Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
25 November 1997Website:
http://www.inotivco.comNext earnings report:
11 December 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 23 Nov 2024 00:54:23 GMTDividend
Analysts recommendations
Institutional Ownership
NOTV Latest News
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering.
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates:
Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare
WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference.
Inotiv stock is experiencing a decline on Tuesday following the release of preliminary results for Q1 2024 by the drug discovery and development services company. The company has reported that its revenue for the six months ending on March 31, 2024 is expected to be $254.5 million.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inotiv, Inc. (NOTV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
In the stock market, identifying the next big opportunity is like observing a celestial phenomenon. Today, through the cosmos of investment, three shining stars are identified for their potential for astronomical valuation possibilities.
- 1(current)
- 2
What type of business is Inotiv?
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
What sector is Inotiv in?
Inotiv is in the Healthcare sector
What industry is Inotiv in?
Inotiv is in the Diagnostics & Research industry
What country is Inotiv from?
Inotiv is headquartered in United States
When did Inotiv go public?
Inotiv initial public offering (IPO) was on 25 November 1997
What is Inotiv website?
https://www.inotivco.com
Is Inotiv in the S&P 500?
No, Inotiv is not included in the S&P 500 index
Is Inotiv in the NASDAQ 100?
No, Inotiv is not included in the NASDAQ 100 index
Is Inotiv in the Dow Jones?
No, Inotiv is not included in the Dow Jones index
When was Inotiv the previous earnings report?
No data
When does Inotiv earnings report?
The next expected earnings date for Inotiv is 11 December 2024